BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23213092)

  • 21. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.
    Minamimoto R; Nakaigawa N; Tateishi U; Suzuki A; Shizukuishi K; Kishida T; Miura T; Makiyama K; Yao M; Kubota Y; Inoue T
    Clin Nucl Med; 2010 Dec; 35(12):918-23. PubMed ID: 21206220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    Bouchelouche K; Choyke PL
    PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
    Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography-computed tomography: a superior and one-stop shop modality for treated head and neck carcinoma compared with conventional tomography.
    Ichpujani VK; Rao SA; Chaturvedi AK; Dewan AK; Choudhary PS
    J Oral Maxillofac Surg; 2014 Nov; 72(11):2319-32. PubMed ID: 25438279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT.
    Coy H; Hsieh K; Wu W; Nagarajan MB; Young JR; Douek ML; Brown MS; Scalzo F; Raman SS
    Abdom Radiol (NY); 2019 Jun; 44(6):2009-2020. PubMed ID: 30778739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of
    Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast - enhanced ultrasonography.
    Xue LY; Lu Q; Huang BJ; Li Z; Li CX; Wen JX; Wang WP
    Eur J Radiol; 2015 Oct; 84(10):1849-56. PubMed ID: 26149528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.
    Gorin MA; Rowe SP; Baras AS; Solnes LB; Ball MW; Pierorazio PM; Pavlovich CP; Epstein JI; Javadi MS; Allaf ME
    Eur Urol; 2016 Mar; 69(3):413-6. PubMed ID: 26386607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with
    van Oostenbrugge TJ; Langenhuijsen JF; Oosterwijk E; Boerman OC; Jenniskens SF; Oyen WJG; Fütterer JJ; Mulders PFA
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1864-1870. PubMed ID: 31768601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contrast-enhanced ultrasound for differentiating benign from malignant solid small renal masses: comparison with contrast-enhanced CT.
    Wei SP; Xu CL; Zhang Q; Zhang QR; Zhao YE; Huang PF; Xie YD; Zhou CS; Tian FL; Yang B
    Abdom Radiol (NY); 2017 Aug; 42(8):2135-2145. PubMed ID: 28331942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of 18F-FDG PET/contrast-enhanced CT in the staging of squamous cell carcinoma of the oral cavity and oropharynx.
    Krabbe CA; Balink H; Roodenburg JL; Dol J; de Visscher JG
    Int J Oral Maxillofac Surg; 2011 Nov; 40(11):1263-70. PubMed ID: 21824748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unusual metastatic sites from renal cell carcinoma detected by 18F-FDG PET/CT scan.
    Aurangabadkar H; Ali Z
    Clin Nucl Med; 2013 Dec; 38(12):e471-3. PubMed ID: 23603603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
    Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
    Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Multiparametric Renal CT Algorithm for Diagnosis of Clear Cell Renal Cell Carcinoma Among Small (≤ 4 cm) Solid Renal Masses.
    Al Nasibi K; Pickovsky JS; Eldehimi F; Flood TA; Lavallee LT; Tsampalieros AK; Schieda N
    AJR Am J Roentgenol; 2022 Nov; 219(5):814-823. PubMed ID: 35766532
    [No Abstract]   [Full Text] [Related]  

  • 40. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.